Edwards Lifesciences presents new trial data, shares near 52 week high

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 13:34.

Edwards Lifesciences (US28176E1082) is back in focus after presenting new clinical trial data on heart disease treatment in New York. The update comes as the EW shares trade on the NYSE and approach their 52 week high, while the Nasdaq-100 shows a weaker trend according to recent market commentary. Intellectia summary of the Edwards trial presentation

Fresh data and a bullish coverage proposal

According to the latest compiled news, Edwards Lifesciences recently presented new data on heart disease treatment, including transcatheter heart valve therapy, at a conference in New York, adding clinical detail for investors watching long-term growth drivers. Finanzen100 note on the Edwards conference appearance The data arrive as the Centers for Medicare & Medicaid Services (CMS) has released an updated national coverage proposal for transcatheter aortic valve replacement, incorporating reimbursement for asymptomatic severe aortic stenosis patients, which directly affects Edwards' TAVR franchise. Coverage of the CMS proposal and Edwards exposure

Evercore ISI calls this updated CMS proposal an "uber bullish scenario" for Edwards Lifesciences, arguing that every key metric optimistic investors were hoping for is reflected in the draft. Evercore ISI view on the CMS coverage draft The research house maintains an Outperform rating on EW and has indicated it would expect Edwards shares to show a low to mid single digit percentage gain on such a reimbursement tailwind, underlining the strategic importance of CMS decisions for high value cardiovascular device makers.

How the stock trades against the sector backdrop

Market data collated for the latest completed session show Edwards Lifesciences shares recently trading around 90.78 US dollars, with an intraday high of 92.46 dollars and a low of 89.33 dollars, on a trading volume of roughly 14.4 million shares. Recent EW price and volume snapshot These levels place the stock near its 52 week high, a marked performance given that some major indices, including the Nasdaq-100, have shown weakness, with the Nasdaq-100 reported down around 0.70 percent in the same broader environment. Market context for Edwards versus the Nasdaq-100

Edwards Lifesciences is a member of the S&P 500 index, which is reported marginally lower, down about 0.07 percent in the commentary referencing the firm's latest stock move. S&P 500 performance versus Edwards Against this backdrop, Edwards' recent positive trading session stands out among medical device peers focused on structural heart disease, a segment that includes companies such as Medtronic and Abbott, where reimbursement clarity and clinical data often trigger sector wide repricing.

The products behind the valves business

Edwards Lifesciences generates most of its revenue from heart valve therapies, especially its portfolio of transcatheter aortic valve replacement systems such as the Sapien family of valves, which are used to treat severe aortic stenosis without open heart surgery. Edwards overview of the Sapien transcatheter valves In addition, Edwards sells surgical heart valves and critical care monitoring solutions, including hemodynamic monitoring platforms and disposable sensors used in intensive care and operating rooms. Company product portfolio summary

Where the Edwards Lifesciences shares trade today

Edwards Lifesciences shares (US28176E1082) most recently traded on the NYSE at about 90.78 US dollars, based on data for the session of 2026-06-26 at approximately 21:00 market time, with the listing denominated in US dollars.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. All data are based on sources believed to be reliable at the time of publication, but no guarantee is given for completeness or accuracy.